A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Is This Study For You?

Let's Get Started!




Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Emily Forbes

Emily Forbes

Study ID

Protocol Number: 23-0328

More information available at ClinicalTrials.gov: NCT05819359

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers